The value of measuring quality of life has been increasingly recognised. It should identify and better describe the damaging effects of the disease or its treatment. This should help the physician and the patient to choose more easily between alternative treatment options. In controlled clinical trials, direct measurement of quality of life is an important outcome measure. When there are no differences in survival it will be possible to recommend a treatment which produces the best quality of life. However, if one treatment produces satisfactory quality of life but unsatisfactory survival then very difficult value judgements are likely to remain whatever methods for measurement are developed.
Interest in measuring quality of life has increased during the 1980s. In 1978, Bardelli and Saracci reported that less than 5% of papers in major cancer journals measured any aspect of quality of life. Since then there has been a major increase, perhaps reflecting the increasing recognition of the limitations and potential hazards of modern cancer treatment and changes in social attitudes. Reviews of this field have been conducted by Fayers & Jones (1983) , Holland (1984) , De Haes & Van Knippenberg (1985) , Ventafridda et al. (1986) , Clark & Fallowfield (1986) , Selby & Robertson (1987) , McDowell & Newell (1987) and Walker & Rosser (1988) .
The widespread feeling that quality bf life should be measured in clinical trials has led to requests for guidance from the Cancer Therapy Committee of the Medical Research Council and other bodies as to the best available methods at present. The Working Party was convened to review existing measures of quality of life in patients with cancer and advise the Cancer Therapy Committee about their use within clinical trials and thus provide a source of advice for all clinical trialists.
Background
We agreed to a pragmatic approach to quality of life and decided that assessment would cover these dimensions: symptoms due to cancer; adverse effects of treatmeant; physical functioning; social interaction; psychological adjustment; sexual functioning; and body image. Any measure recommended must be capable of assessing one or more of these dimensions in a reliable and valid way and be able to be completed by the patient within 10 minutes, be easy to administer, easy to score and reflect changes over time.
We recognised that no scale would fulfil the needs of all clinical trials. So, we would try to recommend core questionnaires which could be applicable to most trials. Additional items could then be added to reflect specific diseases or treatments. We acknowledged that clinicians wanted scales which were short and simple but were concerned that these might be incapable of measuring quality of life in a valid and reliable way. We recognised that general instruments already existed which purported to measure the impact of physical illness (like the Nottingham Health Profile (McEwen, 1988) (1989), 60, 437-440 C The Macmillan Press Ltd., 1989 (ii) (iii) (Gough et al., 1983) .
(ii) Rosser and Kind's distress/disability matrix (Rosser & Kind, 1978) . (iii) Quality of life adjusted years (QUALYS) (Williams, 1985) .
(b) Performance indices (i) Karnofsky et al. (1948) .
(ii) ECOG, Eastern Co-operative Oncology Group (Zubrod et al., 1960) . (iii) Katz activities of daily living (Katz & Akbom, 1976) . (iv) World Health Organization scales (WHO, 1979) . Iszak and Medalie index (1971) . Priestman and Baum (1976) linear self assessment system. Functional living index for cancer (Schipper et al., 1984) . Ontario Cancer Institute quality of life questionnaire (Selby et al., 1984) . Padilla QL questionnaire (Padilla et al., 1981) . QL index (Spitzer et al., 1981) . EORTC QL questionnaire (Aaronson et al., 1986) . Rotterdam symptom check list (Haes et al., 1986) .
Hospital anxiety and depression scale (Zigmong & Snaith, 1983) . General health questionnaire (Goldberg & Hillier, 1979) .
Mode of assessment
Each questionnaire/scale was assessed independently by at least two members of the working party using the agreed criteria and relevant literature. These assessments were circulated to the remaining members of the working party and then discussed to determine the relative advantages and disadvantages of each measure. The word cancer is used in several items and has distressed patients. Validity has been tested only by comparing different groups and by correlation with other self-rating instruments. Performance in detecting changes over time has yet to be assessed. Nor has it been assessed or calibrated against 'gold standard' interviews. Consequently, scores on the component sub-scales are difficult to interpret. There are so few items on each dimension that its ability to measure significant changes over time may be poor. For example, few physical symptoms are included.
These factors prevented the working party from recommending its use in clinical trials despite the attractiveness of simplicity and ease of use.
(iv) Ontario Cancer Institute quality of life scale. The OCI scale comprises 32 linear analogue items which cover all the required dimensions. They are derived from the sickness impact profile and items relating to specific cancer sites. It is easy to use, understand and score. It distinguishes well between patients with breast cancer who are on different treatments and are at different stages of their disease. But the author feels that while it is useful in a research context it is not yet ready for use in clinical trials. It has not been tested in other patients except those with cancer of the ovary. The factor structure has still to be replicated.
(v) Padilla QL scale. This is a short 14 item scale containing three sub-scales. It covers the 'present time' and takes less than 5 minutes to administer. It is easy to score.
Unfortunately, data on reliability and validity are lacking and there are too few items to reflect changes on key dimensions. It appears inferior to the FLIC and OCI Scales.
Linear analogue scales in general can be used to map out differences between different illnesses but are most valid in monitoring the impact of treatment regimes over time. They can tap all dimensions, are simple to administer and score. However, the time periods covered are often unstated or vague. It is difficult to interpret the clinical significance of the scores. Parametric methods of statistical analyses are suspect. There is no evidence that they are superior to categorical rating methods.
(vi) Spitzer QL index. This index measures five areas, including physical activity, daily living, perception of own health, support from family and friends, and outlook on life. The scores are summed to produce an overall score of quality of life. It has the attraction of being simple, easy and quick to administer. It is available in clinician and patient rated versions. It was carefully developed by reference to patients with cancer, patients suffering from other chronic diseases, their relatives, people who were free of disease, doctors, nurses and social workers. Unfortunately, the reduction to five aspects of quality of life reflects an over-reliance on correlations between the different items that go up to make each dimension. Consequently it does not do justice to the different aspects of quality of life. Nor is there evidence that this index has yet been used successfully within clinical trials to reflect change over time. Recent studies have found a poor correlation between the clinician and patient rated versions. They have suggested that the overall score is unduly affected by clinicians' judgements about the extent of the cancer and associated physical disability.
(vii) EORTC questionnaire. This questionnaire was designed for heterogeneous groups of cancer patients. It seeks to measure key dimensions, including symptoms of disease, side-effects of treatment, physical functioning, psychological distress, social interaction, sexuality, body image and satisfaction with medical care. It is a self administered scale and the format varies according to the dimension being addressed. Items on physical activity comprise 'yes or no' responses whereas questions on symptoms use a categorical form asking for answers ranging from 'not at all' to 'very much'. The checklist of symptoms assessed varies according to the type of cancer being studied. It is designed for administration by a nurse within clinics and takes up to 10 minutes to complete. It is easy to score and produces both an overall score and scores on each sub-scale. Unfortunately norms do not yet exist but work is underway to establish norms and check reliability and validity.
While the scale was carefully developed on the basis of existing measures, its reliability and validity have yet to be properly assessed. It has still to be checked against 'gold standard' interviews to see how well it performs. The subscales and factor structure have yet to be replicated. Thus, although it is promising it is still being developed and is probably not ready for inclusion in large scale clinical trials. Initial feedback suggests that the acceptance rate is variable (ranging between 33 and 90%) but it appears to reflect changes over time as well as differences between different diseases and treatments. A major validation study is underway to address the questions of how well it performs within major clinical trials.
(viii) The Rotterdam symptom checklist. This was carefully derived from a pool of items based on existing questionnaires, together with checklists from interviews with cancer patients.
It comprises 38 items and each item is rated on a fourpoint scale (O=not at all, 3=very much). It is well laid out and asks respondents to indicate how much they have experienced particular symptoms over the last week. It is readily administered by nurses and takes 5-10 minutes to complete. All items appear understandable and acceptable. It is easy to score and produces distinct sub-scale scores.
It provides two main sub-scales measuring physical and psychological dimensions. It is considered to be a good, clear and simple questionnaire which has been validated against independent interviews and found to have high sensitivity and specificity in measuring the psychological dimensions. It has been used successfully within busy clinics and seems as effective in advanced cancer patients as in patients with early disease. It seems to measure physical and social dimensions equally well but this requires confirmation.
(d) Psychological dimension (i) Hospital anxiety and depression scale. This 14-item scale has the advantage that it was developed for patients with physical disease and excluded items like tiredness that could be both due to mood disturbance and physical illness. Of the 14 items seven are concerned with anxiety and seven with depression. It is completed by patients and is easy and quick to administer. It has proved capable of measuring change over time within different groups of cancer patients. Recent studies have suggested that a cut-off point of 10/11 distinguishes between patients who are coping well with their cancer and those who have developed morbid anxiety or depression.
It therefore seems a useful tool for measuring the psychological dimensions of quality of life in cancer patients.
(ii) General health questionnaire. This 28-item version includes four sub-scales which measure anxiety, depression, social functioning and physical symptoms. Preliminary evidence suggests that it works less well with cancer patients than those who are free of illness in detecting change over time and determining probable cases of anxiety. It has lower sensitivity and specificity than the more easily administered hospital anxiety and depression scale and Rotterdam symptom check list. Priestman & Baum, 1976; Selby et al., 1984) are useful in highlighting major differences between treatment regimes in respect of adverse effects and disease response but clinical interpretation of scores is difficult. 5. A multi-dimensional scale which is specific to patients with cancer, meets all the assessment criteria and provides scores which have relevance to clinical judgement remains to be developed. This could be done in three phases: (i) In-depth interviews with a representative sample of cancer patients to determine which aspects of quality of life most concern them and change for the better or worse over time.
(ii) The construction of a categorical self-rating questionnaire which measures the most salient aspects of quality of life in a way which reflects both clinically relevant changes and changes which concern the patient. (iii) Validation of this questionnaire cross-sectionally and over time against independent in-depth assessments by trained interviewers.
